Alaunos Therapeutics Inc

Alaunos Therapeutics Inc

TCRT - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$4.04M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Alaunos Therapeutics IncAlaunos Therapeutics Inc-0.8--373%--
$0.54

Current Fair Value

67.5% downside

Overvalued by 67.5% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$4.04 Million
Enterprise Value$3.42 Million
Earnings per Share$-2.2
Beta-1.03
Outstanding Shares2,431,695

Return

Return on Equity-373.12%ROE
Return on Assets-188.89%
Return on Invested Capital-378.78%

Valuation & Multiples

P/E Ratio-0.84P/E Ratio
PEG2.5PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue1140.54
Enterprise Value to EBIT-0.93
Enterprise Value to Net Income-1
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 20, 2026
EPS
-$0.31
Est. -$2.05
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
March 9, 2027
EPS Estimate
-$0.02
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %3.15%▼ 0.57%
Total Invested$67,941▼ 66.78%
Investors Holding21▼ 9.00%

About Alaunos Therapeutics Inc

105 employees

Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled int...